ADAM15

Across TCGA pan-cancer cohorts, ADAM15 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ADAM15 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADAM15 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADAM15 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where ADAM15 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.272	0.580	.006	25	view →
LUAD	DFS	Quartile	All	0.554	1.000	.015	6	view →
UCEC	DFS	Median	II,III,IV	0.872	0.528	.033	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ADAM15–PDAC (DFS)

Open the PDAC breakdown →